

## **AAN 2017 Annual Meeting**

April 22-28, 2017  
Boston, MA

---

Session Type	Plenary Session
Session Title	PL3 - Contemporary Clinical Issues Plenary Session
Date	<b>Monday, April 24, 2017</b>
Time	<b>9:15 a.m.-9:30 a.m. ET</b>
Title	<b>Nusinersen in Infants Diagnosed with Spinal Muscular Atrophy (SMA): Study Design and Initial Interim Efficacy and Safety Findings from the Phase 3 International ENDEAR Study</b> <i>Kuntz N, Farwell W, Zhong ZJ, Sun P, Gheuens S, Schneider E, Finkel R, on behalf of the ENDEAR Study Group</i>

---

Session Type	Oral Presentation
Session Title	S13 - Motor Neuron Diseases: Biomarkers, Outcomes Measures and Therapeutics
Date	<b>Monday, April 24, 2017</b>
Time	<b>1:36 p.m. ET</b>
Title	<b>Reliability of functional outcome measures in spinal muscular atrophy: Results from multi-centered, global, phase 3 clinical trials</b> <i>Glanzman AM, Mazzone ES, Dunaway Young S, Gee R, Rose K, Mayhew A, Yun C, Alexander K, Tennekoon G, Day JW, Finkel RS, Mercuri E, De Vivo DC, Bennet F, Bishop K, Montes J</i>

---



---

Session Type                      Poster Presentation  
Session Title                      P3 – Poster Session III: Child Neurology I  
Date                                      Tuesday, April 25, 2017  
Time                                      5:30 p.m. ET  
Title                                      **P184 – Nusinersen in Symptomatic Children with Later-onset Spinal Muscular Atrophy (SMA): Design of the Phase 3 CHERISH Study**  
*Schneider E, Mignon L, Su J, Baldwin R, Bishop K, Zhong ZJ, Farwell W, and Bennett F, on behalf of the CHERISH study group*

---

Session Type                      Poster Presentation  
Session Title                      P3 – Poster Session III: Child Neurology I  
Date                                      Tuesday, April 25, 2017  
Time                                      5:30 p.m. ET  
Title                                      **P186 – Retrospective Analysis of Healthcare Resource Utilization (HRU) in Patients with Spinal Muscular Atrophy (SMA) in MarketScan®**  
*Teynor M.E, Zhou J, Hou Q, Wells W, Hall E, Avendano*

---

Session Type                      Poster Presentation  
Session Title                      P3 – Poster Session III: Child Neurology I  
Date                                      Tuesday, April 25, 2017  
Time                                      5:30 p.m. ET  
Title                                      **P199 – Estimates of Spinal Muscular Atrophy (SMA): Results from the TREAT NMD Research Program**  
*Lochmüller H, Robertson A, Verhaart IEC, Jones C, Cook SF*

---

Session Type Oral and Poster Presentations  
Session Title Emerging Science Platform Session  
Date **Tuesday, April 25, 2017**  
Time **Presentation at 6:09 p.m. ET**  
**Poster 6:30 p.m.-7:15 p.m.**  
Title **009 – Efficacy and Safety of Nusinersen in Children with Later-onset Spinal Muscular Atrophy (SMA): Interim Results of the Phase 3 CHERISH Study**  
*Finkel R, Mercuri E, Kirschner J, Chiriboga CA, Kuntz N, Darras B, Shieh PB, Saito K, De Vivo DC, Day JW, Mazzone ES, Montes J, Yang Q, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W*

---

Session Type Poster Presentation  
Session Title P4 – Poster Session IV: Child Neurology II  
Date **Wednesday, April 26, 2017**  
Time **5:30 p.m. ET**  
Title **P148 – The Muscular Dystrophy Association (MDA) U.S. Neuromuscular Disease (NMD) Registry: Initial data on patients with Spinal Muscular Atrophy (SMA)**  
*Jones C, Eaton S, Li L, Wang N, Cwik V, Cook S, Gheuens S, Dilley A*

---

Session Type Poster Presentation  
Session Title P4 – Poster Session IV: Child Neurology II  
Date **Wednesday, April 26, 2017**  
Time **5:30 p.m. ET**  
Title **P158 – Healthcare Resource Use in Patients with Diagnosis of Spinal Muscular Atrophy (SMA) in Optum™ U.S. Claims Database**  
*Teynor M.E, Hou Q, Zhou J, Hall E, Wells W, Avendano J*

---



---

Session Type	Oral Presentation
Session Title	S46 - Child Neurology; Molecular Biology to Clinical Trials
Date	<b>Thursday, April 27, 2017</b>
Time	<b>3:54 p.m. ET</b>
Title	<b>003 – Interim Efficacy and Safety Results from the Phase 2 NURTURE Study Evaluating Nusinersen in Presymptomatic Infants with Spinal Muscular Atrophy</b> <i>De Vivo DC, Hwu W-L, Reyna-Medina S, Farwell W, Gheuens S, Sun P, Zhong ZJ, Su J, Schneider E, Bertini E, on behalf of the NURTURE Study Investigators</i>

---